Did you know?

50%-88%

of children are not adherent to prescription medications.6*

*EPRONTIA™ does not have head-to-head data on adherence.

Among children with epilepsy, disliking the taste and difficulty swallowing medication were considered barriers to clinical outcomes7

Oral liquid formulations are often seen as the most acceptable dosage form for children.8

  • Topiramate tablets can become bitter once crushed5

  • Reports have demonstrated that 30%-40% of children and adolescents refuse or are unable to take tablets or capsules9

  • Among children with epilepsy, adherence rates are low—during the first 6 months only 47% of children were adherent to AED therapy10

Strategies to improve adherence include pleasant-tasting medications and liquid formulations.8

Important Safety Information (cont)

Metabolic Acidosis: Metabolic acidosis was commonly observed in adults and pediatric patients in clinical trials and is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by topiramate. Conditions or therapies that predispose patients to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, ketogenic diet, or specific drugs) may be additive to the bicarbonate lowering effects of topiramate. EPRONTIA treatment that causes metabolic acidosis during pregnancy can possibly produce adverse effects on the fetus and might also cause metabolic acidosis in the neonate from possible transfer of topiramate to the fetus. Baseline and periodic serum bicarbonate measurements are recommended during EPRONTIA treatment. If metabolic acidosis develops, consideration should be given to either dose reduction or discontinuation of therapy using dose tapering.

Please see additional Important Safety Information throughout, and the accompanying full Prescribing Information.